Pernix Therapeutics Holdings Company Profile (NASDAQ:PTX)

About Pernix Therapeutics Holdings (NASDAQ:PTX)

Pernix Therapeutics Holdings logoPernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PTX
  • CUSIP: 71426V10
  • Web: www.pernixtx.com
Capitalization:
  • Market Cap: $45.77 million
  • Outstanding Shares: 10,015,000
Average Prices:
  • 50 Day Moving Avg: $4.28
  • 200 Day Moving Avg: $3.80
  • 52 Week Range: $1.83 - $10.40
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $138.13 million
  • Price / Sales: 0.33
  • Book Value: ($14.26) per share
  • Price / Book: -0.31
Profitability:
  • EBIDTA: $1.79 million
  • Net Margins: -125.33%
  • Return on Assets: -36.64%
Debt:
  • Debt-to-Equity Ratio: -0.83%
  • Current Ratio: 0.88%
  • Quick Ratio: 0.79%
Misc:
  • Average Volume: 418,002 shs.
  • Beta: 1.69
  • Short Ratio: 12.27
 

Frequently Asked Questions for Pernix Therapeutics Holdings (NASDAQ:PTX)

What is Pernix Therapeutics Holdings' stock symbol?

Pernix Therapeutics Holdings trades on the NASDAQ under the ticker symbol "PTX."

How were Pernix Therapeutics Holdings' earnings last quarter?

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) posted its quarterly earnings results on Monday, May, 15th. The company reported ($2.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.80) by $1.86. The business had revenue of $29.74 million for the quarter. View Pernix Therapeutics Holdings' Earnings History.

Who are some of Pernix Therapeutics Holdings' key competitors?

Who are Pernix Therapeutics Holdings' key executives?

Pernix Therapeutics Holdings' management team includes the folowing people:

  • John A. Sedor, Chairman of the Board, Chief Executive Officer
  • Graham G. Miao Ph.D., President, Chief Financial Officer, Director
  • Kenneth Robert Pina, Senior Vice President, Chief Compliance Officer, General Counsel
  • Michael Joseph Golembiewski, Vice President, Corporate Controller, Principal Accounting Officer
  • Dennis H. Langer M.D., J.D., Independent Director
  • Gabriel S. Leung, Independent Director
  • Tasos G Konidaris, Non-Executive Independent Director

How do I buy Pernix Therapeutics Holdings stock?

Shares of Pernix Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pernix Therapeutics Holdings' stock price today?

One share of Pernix Therapeutics Holdings stock can currently be purchased for approximately $4.49.


MarketBeat Community Rating for Pernix Therapeutics Holdings (NASDAQ PTX)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pernix Therapeutics Holdings (NASDAQ:PTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Pernix Therapeutics Holdings (NASDAQ:PTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/12/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
3/23/2016S&P Equity ResearchLower Price Target$1.37 -> $1.12N/AView Rating Details
3/16/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/10/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
3/2/2016JMP SecuritiesLower Price TargetMarket Outperform$8.00 -> $6.00N/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Pernix Therapeutics Holdings (NASDAQ:PTX)
Earnings by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Earnings History by Quarter for Pernix Therapeutics Holdings (NASDAQ PTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($4.80)($2.94)$29.74 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.60)($2.99)$48.60 million$41.50 millionViewN/AView Earnings Details
8/11/2016Q2($0.08)($0.47)$46.98 million$36.75 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.42)$44.55 million$32.50 millionViewN/AView Earnings Details
3/10/2016Q4$0.01($0.59)$47.95 million$46.37 millionViewListenView Earnings Details
11/5/2015Q315$0.01$0.08$46.83 million$48.60 millionViewN/AView Earnings Details
8/6/2015Q215($0.01)($0.10)$50.70 million$47.00 millionViewN/AView Earnings Details
5/1/2015Q115$0.04($0.11)$34.55 million$33.90 millionViewN/AView Earnings Details
2/25/2015Q414$0.18$0.25$52.70 million$53.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.02)$28.10 million$31.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.05)($0.16)$26.20 million$17.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.26)$23.65 million$19.10 millionViewN/AView Earnings Details
3/17/2014Q413($0.10)($0.15)$23.82 million$23.90 millionViewN/AView Earnings Details
11/12/2013Q3($0.13)($0.16)$23.06 million$18.30 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.13)($0.16)$20.82 million$20.60 millionViewN/AView Earnings Details
5/10/2013Q1 2013$0.02($0.05)ViewN/AView Earnings Details
11/14/2012Q312$0.03($0.01)$15.04 million$18.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pernix Therapeutics Holdings (NASDAQ:PTX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Pernix Therapeutics Holdings (NASDAQ:PTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pernix Therapeutics Holdings (NASDAQ:PTX)
Insider Ownership Percentage: 5.62%
Institutional Ownership Percentage: 17.34%
Insider Trades by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Institutional Ownership by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Insider Trades by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2015Sanjay S PatelCFOBuy5,000$4.60$23,000.00View SEC Filing  
8/18/2015Douglas DrysdaleCEOBuy8,500$4.69$39,865.00View SEC Filing  
5/6/2015Douglas DrysdaleCEOBuy16,000$6.40$102,400.00View SEC Filing  
5/6/2015Sanjay S PatelCFOBuy2,000$6.42$12,840.00View SEC Filing  
11/3/2014Tracy Simmons CliffordInsiderSell2,246$10.00$22,460.00View SEC Filing  
10/28/2014Tracy Simmons CliffordInsiderSell12,754$10.00$127,540.00View SEC Filing  
5/21/2014James Edward Jr. Smithmajor shareholderSell194,600$6.13$1,192,898.00View SEC Filing  
5/16/2014James Edward Jr. Smithmajor shareholderSell310,200$6.12$1,898,424.00View SEC Filing  
5/14/2014James Edward Jr. Smithmajor shareholderSell289,400$5.47$1,583,018.00View SEC Filing  
5/9/2014James Edward Jr. Smithmajor shareholderSell45,000$4.37$196,650.00View SEC Filing  
5/6/2014James Edward Jr. Smithmajor shareholderSell45,000$4.44$199,800.00View SEC Filing  
5/1/2014James Edward Jr. Smithmajor shareholderSell30,000$4.68$140,400.00View SEC Filing  
4/29/2014James Edward Jr. Smithmajor shareholderSell30,000$4.88$146,400.00View SEC Filing  
4/25/2014James Edward Jr. Smithmajor shareholderSell30,000$5.20$156,000.00View SEC Filing  
4/24/2014James Edward Jr. Smithmajor shareholderSell30,000$4.94$148,200.00View SEC Filing  
4/17/2014James Edward Jr. Smithmajor shareholderSell20,000$4.35$87,000.00View SEC Filing  
4/15/2014James Edward Jr. Smithmajor shareholderSell45,000$4.63$208,350.00View SEC Filing  
4/10/2014James Edward Jr. Smithmajor shareholderSell45,000$5.03$226,350.00View SEC Filing  
4/7/2014James Edward Jr. Smithmajor shareholderSell45,000$4.90$220,500.00View SEC Filing  
4/2/2014Cooper CollinsInsiderSell90,000$5.26$473,400.00View SEC Filing  
4/2/2014James Edward Jr. Smithmajor shareholderSell45,000$5.26$236,700.00View SEC Filing  
3/28/2014James Edward Jr. Smithmajor shareholderSell45,000$5.47$246,150.00View SEC Filing  
3/25/2014James Edward Jr. Smithmajor shareholderSell255,000$4.21$1,073,550.00View SEC Filing  
3/4/2014Cooper CollinsInsiderSell3,590,000$3.40$12,206,000.00View SEC Filing  
2/5/2014Cooper Collinsmajor shareholderSell90,000$2.22$199,800.00View SEC Filing  
1/7/2014Cooper Collinsmajor shareholderSell27,962$2.20$61,516.40View SEC Filing  
1/6/2014Cooper Collinsmajor shareholderSell62,038$2.35$145,789.30View SEC Filing  
12/6/2013Cooper Collinsmajor shareholderSell37,452$2.31$86,514.12View SEC Filing  
12/4/2013Cooper Collinsmajor shareholderSell52,548$2.44$128,217.12View SEC Filing  
11/5/2013Cooper C CollinsMajor ShareholderSell90,000$2.01$180,900.00View SEC Filing  
10/8/2013Cooper Collinsmajor shareholderSell23,364$2.47$57,709.08View SEC Filing  
10/9/2012Michael Cooper PearceDirectorSell1,288$8.00$10,304.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pernix Therapeutics Holdings (NASDAQ:PTX)
Latest Headlines for Pernix Therapeutics Holdings (NASDAQ:PTX)
Source:
DateHeadline
streetinsider.com logoPernix Therapeutics (PTX) Reports Prelim. Q2 Revenue of $33M-$35M
www.streetinsider.com - July 21 at 6:27 AM
finance.yahoo.com logoPernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results
finance.yahoo.com - July 21 at 6:27 AM
finance.yahoo.com logoPernix Commences Refinancing Transactions to Fortify Balance Sheet
finance.yahoo.com - July 21 at 6:27 AM
finanznachrichten.de logoGainers & Losers Of July 13: PTX, ALDR, MNKD, TSRO, TOCA...
www.finanznachrichten.de - July 14 at 7:42 AM
prnewswire.com logoBreakfast Technical Briefing on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, Pernix Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 6:52 AM
americanbankingnews.com logoPernix Therapeutics Holdings, Inc. (PTX) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - July 8 at 10:10 PM
finance.yahoo.com logoPernix Therapeutics Added to Russell Microcap® Index
finance.yahoo.com - June 29 at 6:20 AM
finance.yahoo.com logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : June 13, 2017
finance.yahoo.com - June 13 at 7:29 PM
americanbankingnews.com logoPernix Therapeutics Holdings, Inc. (PTX) Short Interest Update
www.americanbankingnews.com - June 11 at 10:52 PM
finance.yahoo.com logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 31, 2017
finance.yahoo.com - May 31 at 12:58 PM
finance.yahoo.com logoEdited Transcript of PTX earnings conference call or presentation 15-May-17 8:30pm GMT
finance.yahoo.com - May 21 at 6:25 PM
finance.yahoo.com logoPernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 12:12 PM
nasdaq.com logoEarnings Reaction History: Pernix Therapeutics Holdings, Inc., 44.4% Follow-Through Indicator, 11.8% Sensitive - Nasdaq
www.nasdaq.com - May 17 at 8:22 AM
streetinsider.com logoPre-Open Movers 05/16: (AKBA) (ETSY) (SINA) Higher; (PTX) (DKS) (SSYS) Lower (more...)
www.streetinsider.com - May 16 at 7:03 PM
finance.yahoo.com logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 7:03 PM
americanbankingnews.com logoPernix Therapeutics Holdings Inc (PTX) Announces Quarterly Earnings Results, Beats Estimates By $1.86 EPS
www.americanbankingnews.com - May 16 at 1:34 PM
reuters.com logoBRIEF-Pernix Therapeutics qtrly loss per share $2.94
www.reuters.com - May 16 at 9:41 AM
finance.yahoo.com logoInvestor Network: Pernix Therapeutics Holdings, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 6:38 PM
finance.yahoo.com logoPernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 6:38 PM
finance.yahoo.com logoPernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15
finance.yahoo.com - May 8 at 6:45 PM
finance.yahoo.com logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 4, 2017
finance.yahoo.com - May 4 at 7:36 PM
americanbankingnews.com logoPernix Therapeutics Holdings (PTX) Given Daily News Impact Score of 0.56
www.americanbankingnews.com - May 2 at 4:20 PM
finance.yahoo.com logoPernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength
finance.yahoo.com - May 1 at 11:05 AM
americanbankingnews.com logoSomewhat Negative Media Coverage Very Likely to Affect Pernix Therapeutics Holdings (PTX) Stock Price
www.americanbankingnews.com - April 26 at 1:46 PM
finance.yahoo.com logoRennova Health and Pernix Therapeutics Both Led In the Pharma Arena with Significant Share Price Jumps - Yahoo Finance
finance.yahoo.com - April 24 at 2:32 PM
americanbankingnews.com logoPernix Therapeutics Holdings (PTX) Receiving Critical News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 9:05 AM
finance.yahoo.com logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 7:21 PM
finance.yahoo.com logoPlatinex Inc.-Proposed Private Placement
finance.yahoo.com - April 18 at 6:40 PM
americanbankingnews.com logoCritical Media Coverage Very Likely to Effect Pernix Therapeutics Holdings (PTX) Share Price
www.americanbankingnews.com - April 15 at 12:09 PM
finance.yahoo.com logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:43 PM
finance.yahoo.com logoPernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 12:05 PM
finance.yahoo.com logoEdited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT
finance.yahoo.com - March 29 at 8:55 AM
americanbankingnews.com logoPernix Therapeutics Holdings Inc (PTX) Short Interest Down 22.7% in March
www.americanbankingnews.com - March 29 at 8:11 AM
baystreet.ca logoPernix Therapeutics Holdings (PTX) Jumps with Q4 Earnings on Way
www.baystreet.ca - March 28 at 7:12 PM
finance.yahoo.com logoPernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 28 at 7:12 PM
biz.yahoo.com logoPERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 28 at 7:12 PM
benzinga.com logoEarnings Scheduled For March 28, 2017 - Benzinga
www.benzinga.com - March 28 at 9:37 AM
benzinga.com logo25 Stocks Moving In Tuesday's Pre-Market Session - Benzinga
www.benzinga.com - March 28 at 9:37 AM
biz.yahoo.com logoQ4 2016 Pernix Therapeutics Holdings Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 9:37 AM
americanbankingnews.com logoPernix Therapeutics Holdings Inc (PTX) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - March 27 at 7:23 AM
seekingalpha.com logoAn Investor's Rationale To Staying Long Pernix Therapeutics
seekingalpha.com - March 24 at 7:14 PM
finance.yahoo.com logoPernix: An Investor's Rationale to Staying Long
finance.yahoo.com - March 23 at 7:50 PM
streetinsider.com logoPernix Therapeutics (PTX) and GlaxoSmithKline (GSK) Amend ... - StreetInsider.com
www.streetinsider.com - March 23 at 12:19 AM
streetinsider.com logoPernix Therapeutics (PTX) and GlaxoSmithKline (GSK) Amend Interim Settlement Agreement
www.streetinsider.com - March 21 at 7:08 PM
globenewswire.com logoPernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28 - GlobeNewswire (press release)
globenewswire.com - March 16 at 12:34 AM
benzinga.com logo20 Stocks Moving In Monday's Pre-Market Session | Benzinga - Benzinga
www.benzinga.com - March 6 at 6:45 PM
nasdaq.com logoPre-Market Most Active for Feb 23, 2017 : CNHI, CLD, CHK, BAC, TSLA, BSX, LB, PTX, CTRP, NVDA, ERIC, TVIX - Nasdaq
www.nasdaq.com - February 24 at 8:17 AM
globenewswire.com logoPernix Therapeutics Prevails in Zohydro® ER ANDA Litigation - GlobeNewswire (press release)
globenewswire.com - February 24 at 8:17 AM
us.rd.yahoo.com logo8:02 am Pernix Therapeutics confirmed received favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER
us.rd.yahoo.com - February 24 at 12:31 AM
streetinsider.com logoPernix Therapeutics (PTX) Wins Zohydro ER ANDA Litigation
www.streetinsider.com - February 23 at 7:29 PM

Social

Chart

Pernix Therapeutics Holdings (PTX) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff